| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT07284420 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to… |
Trial sites expanded: 10 -> 13 locations |
| 2026-06-02 | NCT07294170 ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy… |
Trial sites expanded: 10 -> 15 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06544499 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With… | Primary Immune Thrombocytopenia (ITP) | Recruiting |
| Phase 2/3 | |||
| NCT04833894 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod… | Generalized Myasthenia Gravis | Recruiting |
| NCT07194850 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age… | Immune Thrombocytopenia (ITP) | Recruiting |
| Phase 2 | |||
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to… | AChR-Ab Seropositive Generalized Myasthenia Gravis | Recruiting |
| Not specified | |||
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy… | Myasthenia Gravis | Recruiting |